{
    "nctId": "NCT00211133",
    "briefTitle": "A Study to Evaluate the Impact of Maintaining Hemoglobin Levels Using Epoetin Alfa in Patients With Metastatic Breast Cancer Receiving Chemotherapy",
    "officialTitle": "A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Impact of Maintaining Hemoglobin Using Eprex (Epoetin Alfa) in Metastatic Breast Carcinoma Subjects Receiving Chemotherapy",
    "overallStatus": "COMPLETED",
    "conditions": "Anemia, Breast Neoplasms, Quality of Life",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 939,
    "primaryOutcomeMeasure": "12-month survival rate, defined as the proportion of patients alive at 12 months after the start of the study.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female patients \\>= 18 years of age with confirmed diagnosis of metastatic breast cancer who are predicted to start chemotherapy for the first time\n* Weight \\> = 40 kg (88 lbs)\n* Postmenopausal for at least 1 year, surgically sterile or practicing an effective method of birth control and have a negative serum pregnancy test at the start of the study\n* Must have signed an informed consent\n\nExclusion Criteria:\n\n* Clinically significant lung, heart, hormone, neurological, gastrointestinal, urinary tract or reproductive system disease\n* Receiving dose intensification chemotherapy for bone marrow or stem cell transplantation\n* Cancer of the brain or brain/spinal cord disease\n* Locally advanced or inflammatory breast cancer as the only symptom of breast cancer\n* Active second primary cancer or documented history of other cancer within the last 3 years\n* Anemia from a cause other than cancer or radiotherapy/chemotherapy\n* History of stoke, clots in the lungs or legs or any other blood clotting disorders\n* Uncontrolled high blood pressure\n* Untreated folate or Vitamin B12 deficiency\n* Treatment with epoetin alfa or other forms of erythropoietin within the last 4 weeks\n* Known hypersensitivity to epoetin alfa or any of its components\n* Pregnant or breast-feeding",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}